Carotid percutaneous transluminal angioplasty/stenting has become an accepted treatment modality for carotid artery stenosis in high-risk patients. There has been an ongoing debate regarding which ...

InspireMD, in partnership with NAMSA, is set to initiate the pivotal, single-arm CGUARDIANS II study to assess the CGuard Prime 80cm carotid stent system’s usage in transcarotid artery ...

A “three-in-one stent” for carotid artery revascularization that includes both an embolic filter and a postdilation balloon appears to offer one of the lowest stroke rates ever reported in patients at ...

Q4 2024 Earnings Call Transcript March 12, 2025 InspireMD, Inc. beats earnings expectations. Reported EPS is $-0.18, ...

(Nasdaq: NSPR), developer of the CGuard™ Prime carotid stent system for the treatment of carotid artery disease and prevention of stroke, today announced financial and operating results for the fourth ...

Carotid artery disease, a progressive buildup of calcium deposits and cholesterol in the primary artery supplying blood to the brain, poses a risk of stroke but there are a few ways to treat it. Dr.

TOLEDO, Ohio and MIAMI, Feb. 13, 2025 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime Carotid Stent System for the prevention of stroke related to carotid ...

StockNews.com began coverage on shares of InspireMD (NYSE:NSPR – Free Report) in a research note released on Monday. The firm issued a sell rating on the stock. Separately, Lake Street Capital started ...

Sixty-nine patients had ICA stenting and 14 had CCA stents (these were CCA bifurcated stents). Sixty-three percent were done for ≥ 70% asymptomatic carotid stenosis and 37% for strokes/transient ...

InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Prime Carotid Stent System for the prevention of stroke related to ...